Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Nobuyuki KatakamiToshihide YokoyamaSatoshi MoritaTatsuro OkamotoYoshiko UrataYoshihiro HattoriYasuo IwamotoYuki SatoNorihiko IkedaToshiaki TakahashiHaruko DagaTetsuya OguriYasuhito FujisakaKazumi NishinoShunichi SugawaraToshiyuki KozukiMasahide OkiNobuyuki YamamotoKazuhiko NakagawaPublished in: International journal of clinical oncology (2022)
No significant differences in OS were observed between the ER and GE arms in all patients with EGFR mutation and those with brain metastasis harboring EGFR mutation.
Keyphrases
- phase iii
- epidermal growth factor receptor
- small cell lung cancer
- open label
- tyrosine kinase
- clinical trial
- advanced non small cell lung cancer
- phase ii
- double blind
- placebo controlled
- resting state
- white matter
- study protocol
- randomized controlled trial
- endoplasmic reticulum
- functional connectivity
- free survival
- breast cancer cells
- estrogen receptor